Turning Ideas into Reality!!

Our in-house Research and Development Centre, located in Pune, India is dedicated to advancing generic and innovative product development for regulated markets. We manage all aspects of development activities, including product formulation, analytical development, validation, stability studies, and technology transfers, to deliver comprehensive solutions for our clients.

We have a fully equipped laboratory with an expert team of professionals. Our R&D team brings years of experience to ensure the highest quality products. We specialize in the development and delivery of tablets, capsules, liquid injections, oral solutions, and modified-release formulations.


  • Solid Orals


  • Oral Liquids


  • Injectables


  • Topicals


  • Ophthalmic Preparations

Solid Orals

  • Immediate Release Tablet (Film-coated)
  • Extended/modified Release (ER Delivery Techniques: Matrix, Osmotic and Reservoir)
  • Delayed Release (DR/Enteric coated) Tablet
  • Buccal/Sublingual Tablet
  • MUPS Technology (Multiunit particulate system: DR/ER pellets into tablets)
  • Orally Disintegrating tablet
  • Soluble tablet
  • Orally Dispersible Tablet
  • Effervescent tablets
  • Chewable Tablet
  • Powder in capsule
  • Mini tablets (IR/Delay release) into capsule
  • Delayed Release pellets in Capsule, Extended-Release Pellets in Capsule

Oral Liquids

Liquids/Solutions

  • Syrups Sugar-Free
  • Syrups Sugar-Based
  • Powder for Solution

Suspensions

  • Liquid Suspensions
  • Carbomer Based suspensions
  • Powder for Suspension

Injectables

  • Powder for Injection
  • Liquid Injections (Prefilled Syringes, Vials, Ampoules)
  • Suspension Injections

Topicals

Creams

  • Emulsion cream
  • Ointment
  • Gel
  • Lotion

Ophthalmic Preparations

  • Drops (Solution / Suspension)
  • Ointment
  • Gel
  • Emulsion

We are committed to innovation, and develop products that enhance patient care through dose reduction, improved administration, and increased efficacy. This includes transforming multiple tablets into delayed-release or sustained-release forms and developing hybrid applications to convert tablets into liquid formulations.

Our team excels in creating complex finished formulations that meet stringent regulatory standards. We focus on:

Generic Products

Value added Generics (Hybrid application products 505(b)2 products)